PAF与绝经后骨质疏松症的研究进展  

Recent research progress of PAF in post-menopausal osteoporosis

作　　者：车艳军[1] 陈亮[1] 杨惠林[1] 

机构地区：[1]苏州大学附属第一医院骨科,苏州215006

出　　处：《中国骨质疏松杂志》2010年第9期695-700,共6页Chinese Journal of Osteoporosis

摘　　要：血小板活化因子(platelet activating factor,PAF)是一种具有多种生物学活性的内源性磷脂介质,是目前发现的作用最强的脂质介质,广泛存在于人体各组织,并在多种生理和病理过程中起重要作用,近年来有研究认为PAF是导致绝经后骨质疏松症的关键性介质,通过增加某些细胞因子和损耗雌激素,可促使PAF生成,从而增强破骨细胞的功能,这就为我们研究绝经后骨质疏松症提供了新的治疗依据[1]。也将为我们治疗绝经后骨质疏松症提供一个新的靶点。Platelet-activating factor （PAF） is a most potent intrinsic lipid mediator currently found, with multi-biological functions. PAF is found existing in wide range of human tissues. It plays an important role in physiological and pathological processes. In recent years, some studies have shown that PAF is a key mediator in postmenopausal osteoporosis （PMOP）. PAF can be generated by increasing some cytokines and decreasing estrogen, leading to increased function of the osteoclast. This provides a new evidence of PMOP treatment research and suggests a new target to treat PMOP.

关 键 词：绝经后骨质疏松症 PAF 受体 机制 

分 类 号：R392[医药卫生—免疫学]